Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Sign Up
Cited by 7,668

The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.

Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial

Stupp, Roger, Hegi, Monika E, Mason, Warren P, van den Bent, Martin J, Taphoorn, Martin JB, Janzer, Robert C, Ludwin, Samuel K, Allgeier, Anouk, Fisher, Barbara, Belanger, Karl, Hau, Peter, Brandes, Alba A, Gijtenbeek, Johanna, Marosi, Christine, Vecht, Charles J, Mokhtari, Karima, Wesseling, Pieter, Villa, Salvador, Eisenhauer, Elizabeth, Gorlia, Thierry, Weller, Michael, Lacombe, Denis, Cairncross, J Gregory, Mirimanoff, René-Olivier·2009·The Lancet Oncology
DOI 10.1016/s1470-2045(09)70025-7
Open this paper in CoChat — free account

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/s1470-2045(09)70025-7

Cites

4 of 4 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 4 references

Research works printed but not linked: 46

  1. Walker, 1980, Randomized comparisons of radiotherapy and nitrosoureas for the treatment of malignant glioma after surgery, N Engl J Med, 303, 1323, 10.1056/NEJM198012043032303 · DOI · Paper page
  2. Laperriere, 2002, Radiotherapy for newly diagnosed malignant glioma in adults: a systematic review, Radiother Oncol, 64, 259, 10.1016/S0167-8140(02)00078-6 · DOI · Paper page
  3. Stewart, 2002, Chemotherapy in adult high-grade glioma: a systematic review and meta-analysis of individual patient data from 12 randomised trials, Lancet, 359, 1011, 10.1016/S0140-6736(02)08091-1 · DOI · Paper page
  4. Hegi, 2005, MGMT gene silencing and benefit from temozolomide in glioblastoma, N Engl J Med, 352, 997, 10.1056/NEJMoa043331 · DOI · Paper page
  5. Pocock, 1975, Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial, Biometrics, 31, 103, 10.2307/2529712 · DOI · Paper page
  6. Freedman, 1976, On the use of Pocock and Simon's method for balancing treatment numbers over prognostic factors in the controlled clinical trial, Biometrics, 32, 691, 10.2307/2529759 · DOI
  7. Ataman, 2004, Quality assurance of the EORTC 26981/22981; NCIC CE3 intergroup trial on radiotherapy with or without temozolomide for newly-diagnosed glioblastoma multiforme: the individual case review, Eur J Cancer, 40, 1724, 10.1016/j.ejca.2004.03.026 · DOI
  8. Taphoorn, 2005, Health-related quality of life in patients with glioblastoma: a randomised controlled trial, Lancet Oncol, 6, 937, 10.1016/S1470-2045(05)70432-0 · DOI · Paper page
  9. Mirimanoff, 2006, Radiotherapy and temozolomide for newly diagnosed glioblastoma: recursive partitioning analysis of the EORTC 26981/22981-NCIC CE3 phase III randomized trial, J Clin Oncol, 24, 2563, 10.1200/JCO.2005.04.5963 · DOI · Paper page
  10. Lamers, 2008, Cost-effectiveness of temozolomide for the treatment of newly diagnosed glioblastoma multiforme: a report from the EORTC 26981/22981 NCI-C CE3 Intergroup Study, Cancer, 112, 1337, 10.1002/cncr.23297 · DOI
  11. Gonzalez, 1994, Accelerated radiotherapy in glioblastoma multiforme: a dose searching prospective study, Radiother Oncol, 32, 98, 10.1016/0167-8140(94)90095-7 · doi:10.1016/0167-8140(94)90095-7
  12. Miralbell, 1999, Accelerated radiotherapy, carbogen, and nicotinamide in glioblastoma multiforme: report of European Organization for Research and Treatment of Cancer trial 22933, J Clin Oncol, 17, 3143, 10.1200/JCO.1999.17.10.3143 · doi:10.1200/jco.1999.17.10.3143
  13. Newlands, 1997, Temozolomide: a review of its discovery, chemical properties, pre-clinical development and clinical trials, Cancer Treat Rev, 23, 35, 10.1016/S0305-7372(97)90019-0 · DOI · Paper page
  14. Brock, 1998, Phase I trial of temozolomide using an extended continuous oral schedule, Cancer Res, 58, 4363
  15. Stupp, 2002, Promising survival for patients with newly diagnosed glioblastoma multiforme treated with concomitant radiation plus temozolomide followed by adjuvant temozolomide, J Clin Oncol, 20, 1375, 10.1200/JCO.2002.20.5.1375 · doi:10.1200/jco.2002.20.5.1375 · Paper page
  16. Wick, 2008, A novel tool to analyse MRI recurrence patterns in glioblastoma, Neuro Oncol, 10, 1019, 10.1215/15228517-2008-058 · DOI
  17. Brandes, 2008, MGMT promoter methylation status can predict the incidence and outcome of pseudoprogression after concomitant radiochemotherapy in newly diagnosed glioblastoma patients, J Clin Oncol, 26, 2192, 10.1200/JCO.2007.14.8163 · DOI · Paper page
  18. 2001, Randomized trial of procarbazine, lomustine and vincristine in the adjuvant treatment of high-grade astrocytoma: a Medical Research Council trial, J Clin Oncol, 19, 509, 10.1200/JCO.2001.19.2.509 · DOI · Paper page
  19. Wedge, 1997, In vitro evaluation of temozolomide combined with X-irradiation, Anticancer Drugs, 8, 92, 10.1097/00001813-199701000-00013 · DOI
  20. Hirose, 2001, p53 effects both the duration of G2/M arrest and the fate of temozolomide-treated human glioblastoma cells, Cancer Res, 61, 1957
  21. van Rijn, 2000, Survival of human glioma cells treated with various combination of temozolomide and X-rays, Int J Radiat Oncol Biol Phys, 47, 779, 10.1016/S0360-3016(99)00539-8 · DOI
  22. Wick, 2002, Prevention of irradiation-induced glioma cell invasion by temozolomide involves caspase 3 activity and cleavage of focal adhesion kinase, Cancer Res, 62, 1915
  23. Chakravarti, 2006, Temozolomide-mediated radiation enhancement in glioblastoma: a report on underlying mechanisms, Clin Cancer Res, 12, 4738, 10.1158/1078-0432.CCR-06-0596 · DOI · Paper page
  24. Curran, 1993, Recursive partitioning analysis of prognostic factors in three Radiation Therapy Oncology Group malignant glioma trials, J Natl Cancer Inst, 85, 704, 10.1093/jnci/85.9.704 · DOI · Paper page
  25. Behin, 2003, Primary brain tumours in adults, Lancet, 361, 323, 10.1016/S0140-6736(03)12328-8 · DOI · Paper page
  26. Gorlia, 2008, Nomograms for predicting survival of patients with newly diagnosed glioblastoma: prognostic factor analysis of EORTC and NCIC trial 26981-22981/CE.3, Lancet Oncol, 9, 29, 10.1016/S1470-2045(07)70384-4 · DOI · Paper page
  27. Schilsky, 2008, How not to treat cancer, Lancet Oncol, 9, 504, 10.1016/S1470-2045(08)70134-7 · doi:10.1016/s1470-2045(08)70134-7
  28. Gerson, 2002, Clinical relevance of MGMT in the treatment of cancer, J Clin Oncol, 20, 2388, 10.1200/JCO.2002.06.110 · DOI · Paper page
  29. Gerson, 2004, MGMT: its role in cancer aetiology and cancer therapeutics, Nat Rev Cancer, 4, 296, 10.1038/nrc1319 · DOI · Paper page
  30. Ochs, 2000, Apoptosis induced by DNA damage O6-methylguanine is Bcl-2 and caspase-9/3 regulated and Fas/caspase-8 independent, Cancer Res, 60, 5815
  31. Esteller, 2000, Inactivation of the DNA-repair gene MGMT and the clinical response of gliomas to alkylating agents, N Engl J Med, 343, 1350, 10.1056/NEJM200011093431901 · DOI · Paper page
  32. Hegi, 2004, Clinical trial substantiates the predictive value of O-6-methylguanine-DNA methyltransferase promoter methylation in glioblastoma patients treated with temozolomide, Clin Cancer Res, 10, 1871, 10.1158/1078-0432.CCR-03-0384 · DOI · Paper page
  33. Jaeckle, 1998, Correlation of tumor O6 methylguanine-DNA methyltransferase levels with survival of malignant astrocytoma patients treated with bis-chloroethylnitrosourea: a Southwest Oncology Group study, J Clin Oncol, 16, 3310, 10.1200/JCO.1998.16.10.3310 · DOI · Paper page
  34. Criniere, 2007, MGMT prognostic impact on glioblastoma is dependent on therapeutic modalities, J Neurooncol, 83, 173, 10.1007/s11060-006-9320-0 · DOI
  35. Hegi, 2008, Correlation of O6-methylguanine methyltransferase (MGMT) promoter methylation with clinical outcomes in glioblastoma and clinical strategies to modulate MGMT activity, J Clin Oncol, 26, 4189, 10.1200/JCO.2007.11.5964 · DOI · Paper page
  36. Murat, 2008, Stem cell-related «self-renewal» signature and high epidermal growth factor receptor expression associated with resistance to concomitant chemoradiotherapy in glioblastoma, J Clin Oncol, 26, 3015, 10.1200/JCO.2007.15.7164 · DOI · Paper page
  37. Vredenburgh, 2007, Phase II trial of bevacizumab and irinotecan in recurrent malignant glioma, Clin Cancer Res, 13, 1253, 10.1158/1078-0432.CCR-06-2309 · DOI · Paper page
  38. Batchelor, 2007, AZD2171, a pan-VEGF receptor tyrosine kinase inhibitor, normalizes tumor vasculature and alleviates edema in glioblastoma patients, Cancer Cell, 11, 83, 10.1016/j.ccr.2006.11.021 · DOI · Paper page
  39. Kreisl, 2008, Phase II trial of single-agent bevacizumab followed by bevacizumab plus irinotecan at tumor progression in recurrent glioblastoma, J Clin Oncol, 27, 740, 10.1200/JCO.2008.16.3055 · DOI · Paper page
  40. Stupp, 2007, Chemoradiotherapy in malignant glioma: standard of care and future directions, J Clin Oncol, 25, 4127, 10.1200/JCO.2007.11.8554 · DOI · Paper page
  41. Reardon, 2008, Randomized phase II study of cilengitide, an integrin-targeting arginine-glycine-aspartic acid peptide, in recurrent glioblastoma multiforme, J Clin Oncol, 26, 5610, 10.1200/JCO.2008.16.7510 · DOI · Paper page
  42. Reardon, 2008, Cilengitide: an integrin-targeting arginine-glycine-aspartic acid peptide with promising activity for glioblastoma multiforme, Expert Opin Investig Drugs, 17, 1225, 10.1517/13543784.17.8.1225 · DOI · Paper page
  43. Omuro, 2007, Lessons learned in the development of targeted therapy for malignant gliomas, Mol Cancer Ther, 6, 1909, 10.1158/1535-7163.MCT-07-0047 · DOI · Paper page
  44. Stupp, 2007, Phase I/IIa trial of cilengitide (EMD121974) and temozolomide with concomitant radiotherapy, followed by temozolomide and cilengitide maintenance therapy in patients with newly diagnosed glioblastoma, J Clin Oncol, 25, 75s
  45. Wen, 2008, Malignant gliomas in adults, N Engl J Med, 359, 492, 10.1056/NEJMra0708126 · DOI · Paper page
  46. van den Bent, 2009, Randomized phase II trial of erlotinib versus temozolomide or carmustine in recurrent glioblastoma, J Clin Oncol, 10.1200/JCO.2008.17.5984 · DOI · Paper page

Cited by

See all 7,668

Metadata

Authors
Stupp, R., Hegi, M. E., Mason, W. P., van den Bent, M. J., Taphoorn, M. J., Janzer, R. C., Ludwin, S. K., Allgeier, A., Fisher, B., Belanger, K., Hau, P., Brandes, A. A., Gijtenbeek, J., Marosi, C., Vecht, C. J., Mokhtari, K., Wesseling, P., Villa, S., Eisenhauer, E., Gorlia, T., Weller, M., Lacombe, D., Cairncross, J. G., & Mirimanoff, R.-O.
Venue
The Lancet Oncology
Publisher
Elsevier BV
Published
2009-05
Volume
10
Issue
5
Pages
459-466
ISSN
1470-2045 (ISSN-L)
DOI
10.1016/s1470-2045(09)70025-7
OpenAlex
W2158681922
Cited by
7,668
References
4
FWCI
127.89
Type
journal article
Language
en
Open access
closed
Licence
  • www.elsevier.com/tdm/userlicense/1.0/ (tdm)
  • www.elsevier.com/legal/tdmrep-license (tdm)

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. https://app.cochat.ai/papers/10.1016/s1470-2045(09)70025-7
The paper
Stupp, R., Hegi, M. E., Mason, W. P., van den Bent, M. J., Taphoorn, M. J., Janzer, R. C., Ludwin, S. K., Allgeier, A., Fisher, B., Belanger, K., Hau, P., Brandes, A. A., Gijtenbeek, J., Marosi, C., Vecht, C. J., Mokhtari, K., Wesseling, P., Villa, S., Eisenhauer, E., . . . Mirimanoff, R.-O. (2009). Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. The Lancet Oncology. https://doi.org/10.1016/s1470-2045(09)70025-7

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.